MED-EL v. Advanced Bionics: Jury Finds MED-EL Willfully Infringed Cochlear Implant Patents
MED-EL filed suit in Delaware in 2018 over eight cochlear implant patents, but Advanced Bionics turned the tables with counterclaims — winning a unanimous jury verdict in December 2023 on willful infringement of two of its own patents and securing $1,443,241 in damages. The case ran for 1,939 days before final judgment.
Plaintiff becomes infringer: how MED-EL lost its own lawsuit
MED-EL Elektromedizinische Gerate GmbH and its US affiliate Med-El Corporation filed suit on October 3, 2018 in the District of Delaware against Advanced Bionics, asserting infringement of up to eight US patents relating to cochlear implant technology. The accused product was Advanced Bionics’ external headpiece used with the HiRes Ultra 3D Cochlear Implant — a flagship device in the highly competitive implantable hearing restoration market.
Advanced Bionics responded with counterclaims that ultimately proved decisive. A jury trial concluded on December 14, 2023 with a unanimous verdict in favor of Advanced Bionics on its counterclaims: MED-EL was found to have willfully infringed claims 2 and 3 of US Patent No. 7,076,308 and claims 16, 19, and 21 of US Patent No. 8,270,647. Final judgment was entered January 24, 2024, awarding Advanced Bionics $1,363,119 on the ‘308 Patent and $80,122 on the ‘647 Patent. The court also entered judgment declaring MED-EL’s own ‘647 Patent invalid on Advanced Bionics’ declaratory judgment counterclaim.
The 1,939-day duration is consistent with complex multi-patent technology disputes in Delaware, where claim construction, multiple IPR proceedings, and trial scheduling routinely extend timelines beyond five years. The willfulness finding is strategically significant — it opens the door to enhanced damages under 35 U.S.C. § 284 and potential attorney fee awards, though the public record does not confirm whether post-verdict motions on enhancement were filed. MED-EL’s original offensive posture ultimately collapsed, and the patent it asserted, US8270647, was itself ruled invalid.
Filing to settlement in 1939 days
1,939-day duration — over 5 years from filing to final judgment in D. Del.
Jury verdict for Advanced Bionics: what the willfulness finding means
Counterclaim victory: defendant becomes damages winner
Advanced Bionics prevailed not by defeating MED-EL’s claims alone, but by asserting its own patent counterclaims and winning them at trial. The jury’s unanimous willfulness finding on claims of both the ‘308 and ‘647 Patents is legally significant: willfulness is a prerequisite for a court to exercise discretion to enhance damages up to three times under 35 U.S.C. § 284 — a separate post-verdict step not reflected in the base $1.44M award.
Willful infringement foundMED-EL exits as infringer, its own patent invalidated
MED-EL initiated this action but left as the losing party on multiple fronts: it was found to have willfully infringed two Advanced Bionics patents, faces a $1.44M damages judgment, and saw its own US8270647 patent declared invalid. Invalidity of the ‘647 Patent eliminates a key asset from MED-EL’s cochlear implant portfolio, weakening its future offensive and defensive posture in this technology space.
Own patent invalidatedAdvanced Bionics secures damages and strengthens its patent portfolio
Advanced Bionics (Sonova AG) emerged with a $1.44M damages award, a willfulness finding that supports potential enhancement motions, and the invalidation of a competitor’s patent. The survival of its ‘308 Patent through trial — with infringement confirmed on specific claims — reinforces enforceability against the cochlear implant sector. The HiRes Ultra 3D platform’s external headpiece is effectively cleared of MED-EL’s original infringement allegations.
$1.44M awarded to ABCochlear implant IP: willfulness risk is real and costly
This verdict signals that in the cochlear implant sector, patent counterclaims can be as dangerous as original claims — and willfulness findings amplify exposure beyond base royalties. Companies operating in the auditory implant space should treat competitor patent portfolios as active enforcement risks. The invalidation of MED-EL’s ‘647 Patent may reshape FTO analyses across hearing restoration device developers and their headpiece interface designs.
Sector-wide enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | MED-EL Elektromedizinische Gerate GmbH | Company | Austrian cochlear implant OEM — holder of US8270647 and seven further hearing device patentsSearch in Eureka ↗ |
| Defendant | Advanced Bionics | Individual | Advanced Bionics LLC/AG (Sonova Group) — cochlear implant manufacturer, counterclaim winnerSearch in Eureka ↗ |
| Plaintiff counsel | Bryan D. Harrison | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Christine Dealy Haynes | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Frederick L. Cottrell , III | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Georg C. Reitboeck | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Joel R. Leeman | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Katherine W. Soule | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Kerry L. Timbers | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Kevin R. Mosier | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Lena M. Cavallo | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Lisa M. Tittemore | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Sara M. Metzler | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Sharona H. Sternberg | Attorney | Counsel for MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Richards Layton & Finger PA | Law Firm | Representing MED-EL Elektromedizinische Gerate GmbHSearch in Eureka ↗ |
| Defendant counsel | Andrew Colin Mayo | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Daniel Shearer | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Gregory Polins | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Hari Santhanam | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Kyle M. Kantarek | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Marcus E. Sernal | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Meredith Zinanni | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Sadaf Misbah | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Steven J. Balick | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant counsel | Tareq Alosh | Attorney | Counsel for Advanced BionicsSearch in Eureka ↗ |
| Defendant law firm | Ashby & Geddes PC | Law Firm | Representing Advanced BionicsSearch in Eureka ↗ |
| Presiding judge | Judge Joshua D. Wolson | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Official order — verbatim text
The January 24, 2024 judgment is notable for its multi-directional resolution: Advanced Bionics prevailed on two infringement counterclaims (claims 2 and 3 of ‘308; claims 16, 19, and 21 of ‘647), a declaratory judgment of invalidity of MED-EL’s own ‘647 Patent, and secured differentiated damages awards per patent. The willfulness finding on both patents is particularly significant — it reflects the jury’s determination that MED-EL had subjective knowledge of the patents and continued infringing conduct regardless, satisfying the Halo Electronics standard. The court’s direction to close the case suggests no pending interlocutory matters, though post-trial motions on enhancement or fees may follow under the same docket.
US7076308 & US8270647 — Cochlear Implant Signal Processing Patents
US7076308B1 (application no. US10/218645) is an Advanced Bionics patent covering signal processing methodology in cochlear implant systems — the core mechanism by which electrical stimulation is delivered to the auditory nerve. The ‘308 Patent survived the full litigation and was found infringed on claims 2 and 3 with willfulness, confirming its enforceability against competing implant architectures. US8270647B2 (application no. US12/397982) was originally asserted by MED-EL as a counterclaim target but was simultaneously challenged via Advanced Bionics’ declaratory judgment counterclaim — and the court found it invalid, eliminating it from MED-EL’s portfolio.
The ‘308 Patent’s confirmed enforceability makes it a live risk for any cochlear implant manufacturer whose external headpiece or signal processing architecture overlaps with its claims. In a market dominated by three global players — Advanced Bionics (Sonova), MED-EL, and Cochlear Limited — patent portfolio depth and enforceability directly shape competitive freedom. The invalidation of MED-EL’s ‘647 Patent removes a previously asserted asset, but MED-EL retains six further patents from its original filing, suggesting continued IP enforcement activity in this space is plausible.
Should you run an FTO against US7076308 and the AB cochlear implant portfolio?
Any company developing cochlear implant systems, external sound processors, or headpiece-to-implant signal interfaces — whether as an OEM, component supplier, or research institution — should treat Advanced Bionics’ US7076308 as an active enforcement risk. This patent survived five years of litigation, a willfulness finding, and a damages award. If your architecture involves stimulation signal coding, headpiece RF communication, or auditory nerve stimulation control, an FTO assessment against claims 2 and 3 of the ‘308 Patent is not optional.
PatSnap Eureka’s FTO Search Agent can map your device’s technical features against the claim scope of US7076308, identify published prior art that may support invalidity arguments, and surface related AB and MED-EL patents in the cochlear implant processing space. Eureka also allows monitoring of litigation activity against specific patents — so if post-trial motions or appeals follow this verdict, you’ll be informed before it affects your commercial strategy.
Run a freedom-to-operate analysis on US7076308B1 to assess your product’s exposure
Run FTO in Eureka →Similar cochlear implant patent litigation in US District Courts
Cases involving cochlear implant signal processing and headpiece patents in US District Courts, including other MED-EL and Advanced Bionics enforcement actions.
What this case signals for the cochlear implant IP landscape
A five-year Delaware battle ending in counterclaim victory and patent invalidation reshapes competitive dynamics in hearing implant IP.
Offensive patent suits carry symmetric counterclaim risk in medtech
MED-EL’s decision to file first in 2018 created the litigation vehicle through which Advanced Bionics ultimately won. In complex medtech patent disputes, defendants routinely assemble counterclaim portfolios — firms should audit competitor-held patents before filing suit to assess counterclaim exposure.
Willfulness findings are achievable even against sophisticated OEMs
The jury’s willfulness finding against MED-EL — a major global cochlear implant manufacturer — demonstrates that knowledge of competitor patents combined with continued product sales can meet the Halo standard. Documentation of design-around efforts or freedom-to-operate opinions becomes critical risk mitigation for any party in active litigation.
MED-EL v Advanced — key questions answered
Advanced Bionics won. A unanimous jury verdict on December 14, 2023 found MED-EL willfully infringed Advanced Bionics’ US7076308 (claims 2–3) and US8270647 (claims 16, 19, 21). Final judgment entered January 24, 2024 awarded Advanced Bionics $1,363,119 on the ‘308 Patent and $80,122 on the ‘647 Patent. MED-EL’s own ‘647 Patent was also declared invalid.
Eight patents were involved. MED-EL originally asserted six patents including US8155747, US6761681, USRE046057, US7167847, US8634909, and US8155746. Advanced Bionics counterclaimed on US7076308 and US8270647. The jury verdict focused on the two AB counterclaim patents; MED-EL’s ‘647 Patent was separately declared invalid.
A willfulness finding under Halo Electronics v. Pulse Electronics enables the district court to enhance damages up to three times the jury award under 35 U.S.C. § 284. Applied to the $1.44M base award, this could theoretically increase MED-EL’s exposure to approximately $4.3M, though enhancement is discretionary and the court may also consider attorney fees under § 285. The public record does not confirm whether post-verdict enhancement motions were filed.
The accused product in MED-EL’s original complaint was Advanced Bionics’ external headpiece used with the HiRes Ultra 3D Cochlear Implant. Advanced Bionics’ counterclaims accused MED-EL products of infringing its own cochlear implant patents, resulting in the damages award against MED-EL.
Yes. The January 24, 2024 judgment includes an entry in favor of Advanced Bionics on its First Counterclaim for Declaratory Judgment of Invalidity of US Patent No. 8,270,647. This means the ‘647 Patent — originally part of MED-EL’s portfolio — was ruled invalid by the Delaware District Court, removing it from MED-EL’s enforceable patent assets.
PatSnap Eureka searches patents and litigation data to answer instantly.